US FDA’s Marks Worries Someone May Stop Hybrid Work System
CBER Director Peter Marks said the FDA’s remote and in-person work system is functioning well and continues to help recruitment.
You may also be interested in...
Until hiring is completed, the new Office of Therapeutic Products director must head an office and two divisions she supervises in addition to her actual duties.
The CBER director has worried that ‘someone’ might try to end the US FDA’s hybrid work policy. Now the push against it is bipartisan.
Agency employees will have on-site, telework and remote possibilities, but options will depend on the center, office and job duties.